Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CHU d'Estaing

Verified siteinfo

France 1 place Lucie et Raymond Aubrax, 63100 Clermont Ferrand, France

  • 9 trials recruiting
  • Chronic myeloid leukaemia · Acute myeloid leukaemia · Blastic plasmacytoid dendritic cell neoplasia
  • Adults and children

About Specializations

CHU d'Estaing in Clermont Ferrand, France specialises in clinical trials of conditions such as Chronic myeloid leukaemia, Acute myeloid leukaemia, Blastic plasmacytoid dendritic cell neoplasia, Colon cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Gastroenterology

The medical center is at the forefront of gastroenterology, with a particular focus on Crohn's disease. This chronic inflammatory condition of the gastrointestinal tract is a key area of research, aiming to improve patient outcomes and quality of life.

  • Post-operative recurrence prevention
  • Endoscopic assessment techniques
  • Innovative therapeutic interventions

Through its research, the center is pioneering new approaches to manage and prevent the recurrence of Crohn's disease following surgical interventions, utilizing advanced endoscopic techniques to monitor disease progression.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
1 place Lucie et Raymond Aubrax63100 Clermont FerrandFrance
Open in maps ↗
Recruiting now
9 trials
Conditions studied
19
Partner status
Verified site

More sites in Clermont FerrandFrance

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

12 clinical trials

Blastic plasmacytoid dendritic cell neoplasia

Recruiting

Study on the Effectiveness and Safety of Tagraxofusp and Venetoclax for Adults with Untreated Blastic Plasmacytoid Dendritic Cell Neoplasm

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tagraxofusp
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Crohn's disease

Recruiting

Study on EXL01 for Preventing Crohn's Disease Recurrence After Surgery in Patients

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:EXL01
  • Sponsor:Groupe De Recherche Sur Les Maladies Inflammatoires Digestives

Polycythaemia vera+4

Recruiting

Study on Apixaban, Rivaroxaban, and Aspirin for Preventing Blood Clots in Patients with JAK2V617F-Positive Myeloproliferative Neoplasms

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Chronic myeloid leukaemia

Recruiting

Study of Pioglitazone and Avelumab Combined with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Complete Cytogenetic Response

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Centre Hospitalier De Versailles

Tumour of ampulla of Vater

Recruiting

Study Comparing mFOLFIRINOX and Capecitabine or Gemcitabine for Patients with Resected Ampullary Adenocarcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Rhabdomyosarcoma

Recruiting

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:The University Of Birmingham

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:Institut Gustave Roussy

Gastrooesophageal cancer+3

Recruiting

Study of Oxaliplatin, Nivolumab, and Trifluridine/Tipiracil for Patients with Advanced Gastric, Esophageal, or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Unicancer

Neuroendocrine carcinoma

Recruiting

Study Comparing FOLFIRINOX and Cisplatin-Etoposide for Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Colon cancer

Not recruiting

Study on Chemotherapy with Levoleucovorin, Capecitabine, and Folinic Acid for Patients Aged 70+ After Stage III Colon Cancer Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Capecitabine
  • Sponsor:Fondation Franc.Cancerologie Digestive

Colorectal cancer metastatic

Not recruiting

Study of Pembrolizumab with Drug Combination for Patients with Microsatellite Stable Metastatic Colorectal Cancer with High Immune Infiltrate

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondation Franc.Cancerologie Digestive

Acute myeloid leukaemia+1

Not recruiting

Study of three different doses of busulfan with fludarabine and thymoglobuline in stem cell transplantation for patients with high-risk myeloid blood disorders

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Institut Paoli-Calmettes
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.